| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/04/2011 | CN102038705A Preparation method of green treatment and health-care liquid medicine |
| 05/04/2011 | CN102038701A Anti-depression application of albiflorin |
| 05/04/2011 | CN102038699A Novel application of paeoniflorin to inflammation resistance |
| 05/04/2011 | CN102038697A Anti-anxiety medicament and application thereof |
| 05/04/2011 | CN102038694A Syringin pharmaceutical composition and preparation method and application thereof |
| 05/04/2011 | CN102038685A Blonanserin medicine composition with capacity of improving oral absorbability |
| 05/04/2011 | CN102038680A Medical composition |
| 05/04/2011 | CN102038669A Use of agomelatin in the manufacture of a medicament for the treatment of bipolar disorders |
| 05/04/2011 | CN102038660A Gastrodine solid dispersible tablet preparation and preparation method thereof |
| 05/04/2011 | CN102038659A Pills taking nicotine as main active ingredient and preparation method thereof |
| 05/04/2011 | CN102038657A Levetiracetam tablet and preparation method thereof |
| 05/04/2011 | CN102038653A Donepezil hydrochloride orally disintegrating tablet and preparation method thereof |
| 05/04/2011 | CN101816766B Chinese medicinal composition for treating tristimania |
| 05/04/2011 | CN101690814B Traditional Chinese medicine monomer having function of promoting growth of motoneuron |
| 05/04/2011 | CN101596261B Medicament for treating hydrocephalus and preparation method thereof |
| 05/04/2011 | CN101591300B Novel method for synthesizing lacosamide |
| 05/04/2011 | CN101575311B Method for preparing epiphysin |
| 05/04/2011 | CN101524370B Production technology of pig brain protolysate |
| 05/04/2011 | CN101411716B Use of polygonin for preparing product for resisting dementia |
| 05/04/2011 | CN101396334B Curcumin lipid carrier and preparation method thereof |
| 05/04/2011 | CN101314001B Chinese medicinal composition for treating vascular dementia and preparation method thereof |
| 05/04/2011 | CN101270110B Novel sulfonyl substituted benzophenone oxide compounds, prepraring method and application thereof |
| 05/04/2011 | CN101238894B Health food with sleep-improving function and its preparation |
| 05/04/2011 | CN101214250B Use of hederagenin and its derivatives in preparing antidepressant product |
| 05/04/2011 | CN101203492B Substituted butyrophenone derivatives |
| 05/04/2011 | CN101142180B Pyrrolidine derivatives as histamine h3 receptor antagonists |
| 05/04/2011 | CN101091706B Excitant of dopamine transport protein and usage |
| 05/04/2011 | CN101072784B Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of making them |
| 05/04/2011 | CN101032483B Hydantoin derivative for adjusting estrogen receptor activity and application thereof |
| 05/04/2011 | CN101019627B Micro jet and instantaneous high pressure process of preparing whole lily powder |
| 05/03/2011 | USRE42327 Medicinal compositions improving brain function and method for improving brain function |
| 05/03/2011 | US7935825 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 05/03/2011 | US7935786 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 05/03/2011 | US7935729 Use of triglyceride oils containing γ-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease |
| 05/03/2011 | US7935718 Treatment of dyskinesia |
| 05/03/2011 | US7935714 Compositions for sleeping disorders |
| 05/03/2011 | US7935680 Methods for modulating the axonal growth of central nervous system neurons |
| 05/03/2011 | US7935671 Pantropic neurotrophic factors |
| 05/03/2011 | US7935365 Glycerophospholipids for the improvement of cognitive functions |
| 05/03/2011 | US7935339 Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
| 05/03/2011 | US7935333 Vaccine against brain protein; antiepileptic agents |
| 05/03/2011 | CA2639210C Dibenzo (b,f) azepine intermediates |
| 05/03/2011 | CA2631581C Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
| 05/03/2011 | CA2599890C Substituted pyridine derivatives |
| 05/03/2011 | CA2576067C Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
| 05/03/2011 | CA2554550C Hydroisoindoline tachykinin receptor antagonists |
| 05/03/2011 | CA2551789C Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders |
| 05/03/2011 | CA2489824C Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases |
| 05/03/2011 | CA2477879C Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect |
| 05/03/2011 | CA2476343C 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors |
| 05/03/2011 | CA2473988C Drechsleranol derivatives, method for the production and use thereof |
| 05/03/2011 | CA2473026C 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| 05/03/2011 | CA2467517C Substituted benzoxazoles and analogues as estrogenic agents |
| 05/03/2011 | CA2443632C Timed pulse release composition |
| 05/03/2011 | CA2440438C Heterocyclic compounds |
| 05/03/2011 | CA2440091C Prodrugs of anticancer agents employing substituted aromatic acids |
| 05/03/2011 | CA2400778C Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |
| 05/03/2011 | CA2390671C Methods for screening compounds active on neurons |
| 05/03/2011 | CA2342966C Gene alteration in the gene for the gbeta3 subunit of the human g protein |
| 05/03/2011 | CA2206509C Novel hedgehog-derived polypeptides |
| 04/28/2011 | WO2011050262A2 Dual variable domain immunoglobulins and uses thereof |
| 04/28/2011 | WO2011050202A1 Fused heterocyclic compounds as orexin receptor modulators |
| 04/28/2011 | WO2011050200A1 Fused heterocyclic compounds as orexin receptor modulators |
| 04/28/2011 | WO2011050198A1 Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| 04/28/2011 | WO2011050192A1 Modulation of axon degeneration |
| 04/28/2011 | WO2011050095A2 Prevention and treatment of post-operative cognitive dysfunction (pocd) |
| 04/28/2011 | WO2011050030A1 Alpha adrenergic receptor modulators |
| 04/28/2011 | WO2011049948A2 Neuroprotection and myelin repair using nestorone® |
| 04/28/2011 | WO2011049792A1 Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis |
| 04/28/2011 | WO2011049758A1 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| 04/28/2011 | WO2011049475A1 The new application of 2-pyrrolidone derivatives |
| 04/28/2011 | WO2011049346A2 Compositions for improving migration potential of stem cells |
| 04/28/2011 | WO2011049082A1 INTEGRIN α8Β1-SPECIFIC MONOCLONAL ANTIBODY |
| 04/28/2011 | WO2011049053A1 Intestinal mucosa-inherent myeloid cells inhibiting t cell activation and utilization of same |
| 04/28/2011 | WO2011049038A1 Transdermally absorbable donepezil-containing preparation |
| 04/28/2011 | WO2011048936A1 Aminothiazole derivative |
| 04/28/2011 | WO2011048525A1 Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators |
| 04/28/2011 | WO2011048409A1 Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| 04/28/2011 | WO2011048350A1 Treatment using reprogrammed mature adult cells |
| 04/28/2011 | WO2011048208A1 Causal therapy of diseases or conditions associated with cns or pns demyelination |
| 04/28/2011 | WO2011048150A1 Use of 1h-quinazoline-2,4-diones |
| 04/28/2011 | WO2011047860A1 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives |
| 04/28/2011 | WO2011047770A2 Pyrazolopyrimidine derivatives |
| 04/28/2011 | WO2011047767A1 Novel polymorphic forms of (s)-2-[-4-(3-fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
| 04/28/2011 | WO2011047576A1 Use of albiflorin for anti-depression |
| 04/28/2011 | WO2011047412A1 Tyrosine and l-dopa for reducing l-dopa incorporation into proteins |
| 04/28/2011 | WO2011027060A3 Oxytocin treatment for behavioral characteristics associated with autism and shyness disorder |
| 04/28/2011 | WO2011008675A3 Catecholamine compounds, compositions, and formulations, and methods of using the same |
| 04/28/2011 | WO2011002103A3 A cycloalkane derivative |
| 04/28/2011 | WO2010150995A3 Compositions for treating drug addiction and improving addiction-related behavior |
| 04/28/2011 | WO2010148177A3 Compounds, compositions, methods of synthesis, and methods of treatment |
| 04/28/2011 | WO2010141666A3 Modulating endogenous beta-endorphin levels |
| 04/28/2011 | WO2010141592A3 Chemical fragment screening and assembly utilizing common chemistry for nmr probe introduction and fragment linkage |
| 04/28/2011 | WO2010132873A3 Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase |
| 04/28/2011 | WO2010132821A3 Methods and compositions for treating degenerative and ischemic disorders |
| 04/28/2011 | WO2010086454A9 N-(phenyl or pyridyl)prenylamine derivatives for the treatment of obesity, diabetes, cardiovascular diseases and other adiponectin-related diseases |
| 04/28/2011 | WO2009069002A3 Low dose colony stimulating factors to treat amyloidosis |
| 04/28/2011 | US20110098468 Nk1 antagonists |
| 04/28/2011 | US20110098361 Composition to enhance the bioavailability of curcumin |
| 04/28/2011 | US20110098360 Adamantane derivative for inhibiting toxicity of amyloid oligomer |